Yahoo Finance

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

WALTHAM, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today ...
Pharmabiz

Damora Therapeutics begins phase 1/1b CLARITY-101 trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis

Damora Therapeutics, Inc., a biotechnology company working to fundamentally redefine care for patients with blood disorders, announced the initiation of the global phase 1/1b CLARITY-101 clinical ...
manilatimes

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical ...